RT Journal Article
SR Electronic
T1 Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.09.20091447
DO 10.1101/2020.05.09.20091447
A1 Dennis Lapuente
A1 Clara Maier
A1 Pascal Irrgang
A1 Julian Hübner
A1 Sophia Peter
A1 Markus Hoffmann
A1 Armin Ensser
A1 Katharina Ziegler
A1 Thomas H. Winkler
A1 Torsten Birkholz
A1 Andreas E. Kremer
A1 Philipp Steininger
A1 Klaus Korn
A1 Frank Neipel
A1 Klaus Überla
A1 Matthias Tenbusch
YR 2020
UL http://medrxiv.org/content/early/2020/05/13/2020.05.09.20091447.abstract
AB SARS-CoV-2 has emerged as a previously unknown zoonotic coronavirus that spread worldwide causing a serious pandemic. While reliable nucleic acid-based diagnostic assays were rapidly available, there exists only a limited number of validated serological assays. Here, we evaluated a novel flow cytometric approach based on antigen-expressing HEK 293T cells to assess spike-specific IgG and IgM antibody responses. Analyses of 201 pre-COVID-19 sera proved a high assay specificity in comparison to commercially available CLIA and ELISA systems, while also revealing the highest sensitivity in specimens from PCR-confirmed SARS-CoV-2 infected patients. Additionally, a soluble Angiotensin-Converting-Enzyme 2 (ACE-2) variant was established as external standard to quantify spike-specific antibody responses on different assay platforms. In conclusion, our newly established flow cytometric assay allows sensitive and quantitative detection of SARS-CoV-2-specific antibodies, which can be easily adopted in different laboratories and does not rely on external supply of assay kits.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript.